Segment information

6 Months Ended

Jun. 30, 2012

Segment information [Abstract]

Segment information

12. Segment information

For financial reporting purposes, the Company reports financial information for two business segments: Biodefense and Biosciences. The Company's two business segments, or divisions, engage in business activities for which discrete financial information is reviewed by the chief operating decision maker. The accounting policies of the reportable segments are the same as those described in the summary of significant accounting policies. The Company's reportable segments are business units that offer different products and product candidates and are managed separately because they manufacture and develop distinct products with different development processes.

In the Biodefense division, the Company develops, manufactures and commercializes vaccines and antibody therapies for use against biological agents that are potential weapons of bioterrorism. Revenues in this segment are primarily from sales of the Company's FDA-licensed product, BioThrax® (Anthrax Vaccine Adsorbed), to the U.S. government. In the Biosciences division, the Company develops vaccines, protein therapeutics and technology platforms for use against infectious diseases, oncology, autoimmune and inflammatory disorders and other medical conditions that have resulted in significant unmet or underserved public health needs.  The Biosciences division consists of two business units, therapeutics and vaccines, and is comprised of development stage product candidates. The "All Other" segment relates to the general operating costs of the Company and includes costs of the centralized services departments, which are not allocated to the other segments, as well as spending on activities that are not classified as Biodefense or Biosciences. The assets in this segment consist primarily of cash.

	Reportable Segments
(in thousands)	Biodefense		Biosciences			All Other			Total
Three Months Ended June 30, 2012
External revenue	$	66,964	$	3,415		$	-		$	70,379
Net income (loss)		24,335		(14,963	)		(1,740	)		7,632
Total assets		257,377		129,565			140,198			527,140
Three Months Ended June 30, 2011
External revenue	$	83,685	$	4,456		$	-		$	88,141
Net income (loss)		36,902		(20,580	)		(2,112	)		14,210
Total assets		217,057		121,209			155,718			493,984

	Reportable Segments
(in thousands)	Biodefense		Biosciences			All Other			Total
Six Months Ended June 30, 2012
External revenue	$	115,600	$	5,090		$	-		$	120,690
Net income (loss)		38,601		(34,854	)		(2,947	)		800
Total assets		257,377		129,565			140,198			527,140
Six Months Ended June 30, 2011
External revenue	$	99,185	$	7,489		$	-		$	106,674
Net income (loss)		30,810		(35,705	)		(2,292	)		(7,187	)
Total assets		217,057		121,209			155,718			493,984